Aileron CEO Manuel Aivado resigns; President Brian Windsor named CEO effective March 11, 2024

Rein Therapeutics, Inc.

Manuel Aivado steps down as CEO effective March 11, 2024, remains on the Board.
Brian Windsor, previously President and COO since October 2023, appointed CEO and director.
Windsor led Lung Therapeutics prior to its acquisition by Aileron in October 2023.
Aivado receives severance: 18 months base salary, 1.5x target bonus, equity acceleration, COBRA.
Resignation is not due to any disagreement with company operations, policies, or practices.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Brian Windsor

Chief Executive Officer

RNTX · Rein Therapeutics, Inc.

Effective: 2024-03-11
Filed: March 15, 2024, 7:59 PM ET

the Board elected Brian Windsor, Ph.D., as the Chief Executive Officer of the Company and a member of the Board, effective as of March 11, 2024

Departed

Manuel C. Alves-Aivado

Chief Executive Officer

RNTX · Rein Therapeutics, Inc.

Effective: 2024-03-11
Successor: Brian Windsor
Filed: March 15, 2024, 7:59 PM ET

Manuel C. Alves-Aivado, M.D., Ph.D., agreed that his employment with the Company would cease and he would resign from his position as Chief Executive Officer of the Company, effective as of March 11, 2024

Appointed

Brian Windsor

Director

RNTX · Rein Therapeutics, Inc.

Effective: 2024-03-11
Filed: March 15, 2024, 7:59 PM ET

the Board elected Brian Windsor, Ph.D., as the Chief Executive Officer of the Company and a member of the Board, effective as of March 11, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Brian Windsor was elected as Chief Executive Officer at Rein Therapeutics, Inc..

Action: elected
Role: Chief Executive Officer

Exact text from the filing

the Board elected Brian Windsor, Ph.D., as the Chief Executive Officer of the Company and a member of the Board, effective as of March 11, 2024

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Manuel C. Alves-Aivado resigned as Chief Executive Officer at Rein Therapeutics, Inc..

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

Manuel C. Alves-Aivado, M.D., Ph.D., agreed that his employment with the Company would cease and he would resign from his position as Chief Executive Officer of the Company, effective as of March 11, 2024

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Brian Windsor was elected as Director at Rein Therapeutics, Inc..

Action: elected
Role: Director

Exact text from the filing

the Board elected Brian Windsor, Ph.D., as the Chief Executive Officer of the Company and a member of the Board, effective as of March 11, 2024

View on SEC.gov

Rein Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-068566

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.